Trial Profile
Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Gusperimus (Primary)
- Indications Granulomatosis with polyangiitis
- Focus Therapeutic Use
- Sponsors Nippon Kayaku
- 29 Mar 2014 New trial record